Boceprevir for Untreated Chronic HCV Genotype 1 Infection | Zendy

Fred Poordad | Zendy; Jonathan McCone | Zendy; Bruce R. Bacon | Zendy; Savino Bruno | Zendy; Michael P. Manns | Zendy; Mark Sulkowski | Zendy; Ira M. Jacobson | Zendy; K. Rajender Reddy | Zendy; Zachary Goodman | Zendy; Navdeep Boparai | Zendy; Mark J. DiNubile | Zendy; Vilma Sniukiene | Zendy; Clifford A. Brass | Zendy; Janice K. Albrecht | Zendy; JeanPierre Bronowicki | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

Author(s) -

Fred Poordad,

Jonathan McCone,

Bruce R. Bacon,

Savino Bruno,

Michael P. Manns,

Mark Sulkowski,

Ira M. Jacobson,

K. Rajender Reddy,

Zachary Goodman,

Navdeep Boparai,

Mark J. DiNubile,

Vilma Sniukiene,

Clifford A. Brass,

Janice K. Albrecht,

JeanPierre Bronowicki

Publication year - 2011

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1010494

Subject(s) - boceprevir , medicine , ribavirin , hepatitis c virus , genotype , virology , telaprevir , protease inhibitor (pharmacology) , chronic hepatitis , virus , immunology , viral load , gene , antiretroviral therapy , biology , biochemistry

Peginterferon-ribavirin therapy is the current standard of care for chronic infection with hepatitis C virus (HCV). The rate of sustained virologic response has been below 50% in cases of HCV genotype 1 infection. Boceprevir, a potent oral HCV-protease inhibitor, has been evaluated as an additional treatment in phase 1 and phase 2 studies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research